Berry Genomics Co.,Ltd (000710.SZ)
- Previous Close
13.68 - Open
12.92 - Bid 14.19 x --
- Ask 14.20 x --
- Day's Range
13.39 - 14.49 - 52 Week Range
6.66 - 19.55 - Volume
42,887,050 - Avg. Volume
41,511,331 - Market Cap (intraday)
5.016B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.58 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 25, 2001
- 1y Target Est
--
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia. The company was founded in 1997 and is headquartered in Beijing, China.
www.berrygenomics.com1,402
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 000710.SZ
View MorePerformance Overview: 000710.SZ
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000710.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000710.SZ
View MoreValuation Measures
Market Cap
5.02B
Enterprise Value
4.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.63
Price/Book (mrq)
3.01
Enterprise Value/Revenue
4.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-20.38%
Return on Assets (ttm)
-3.45%
Return on Equity (ttm)
-11.27%
Revenue (ttm)
1.02B
Net Income Avi to Common (ttm)
-207.13M
Diluted EPS (ttm)
-0.58
Balance Sheet and Cash Flow
Total Cash (mrq)
362.11M
Total Debt/Equity (mrq)
15.48%
Levered Free Cash Flow (ttm)
34.19M